Drug Discovery World - Pharma, Drug Development, Therapeutics, Chemistry-logo

Drug Discovery World - Pharma, Drug Development, Therapeutics, Chemistry

Science Podcasts >

More Information


United Kingdom






The Use of Next-Generation Sequencing in Drug Development

This episode summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making. Next-generation sequencing (NGS) has moved from the realm of research into those of clinical development, drug approval and clinical diagnostics, as the cost has...


Artificial Intelligence (AI) & Biopharma R&D IT

This episode discusses issues around artificial intelligence & Biopharma R&D IT, and outlines how AI can be a potentially transformative technology for the biopharmaceutical and healthcare industries. "...R&D productivity remains an ongoing concern. Artificial Intelligence and the accompanying analytics are now so advanced that these tools promise to improve the traditional drug target selection and R&D process." As noted in the Ernst & Young report Beyond borders Biotechnology report...


Automating Flow Cytometry for Cell-Based Screening in Drug Discovery

Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications. Most commonly used in the fields of immunology and haematology, recent improvements in instrument automation and throughput mean that the technique is now emerging as an increasingly attractive high-throughput screening (HTS) platform in drug discovery too. Flow cytometry is a widely-used analytical method that uses light to count and characterise heterogeneous...


The Cancer Conundrum - Increasing Clinical Success With Early Phase Drug Discovery

Increasing clinical success by implementing improved methodologies in early phase drug discovery. Using primary cells and 3D culture models to enhance cancer drug discovery. The high stakes of drug discovery and development lead pharmaceutical companies to be meticulous in ensuring a target is validated and that compounds are effective against this target in order to have the best chance of developing a successful drug. Taking into account the long-term investment of both time and money...


Targeting Kinases for Drug Discovery (Bonus Webinar Episode)

Welcome to this bonus episode of the Drug Discovery Podcast. Today’s episode is an hour long episode taken from one of our DDW Webinars. Kinases are one of the most widely-studied drug target classes, with over 20 years in the spotlight for drug discovery research. Selecting optimized assays for screening, hit validation, selectivity profiling, and lead optimization, represents key steps towards identifying candidate compounds for preclinical and clinical development. With over 500...


Emerging Drug Discovery Alliance Models

The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging. Advancing an idea from an academic or basic research setting into a therapeutic product that benefits patients is time- and capital-intensive, sometimes inefficient and – frustratingly often – unsuccessful. This reality has led entities in the early drug discovery and development ecosystem to utilise new alliance-based partnership models to increase...


Novel Drug Targets From Phenotypic Screening

Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug receptors that can then be exploited through target driven means. Although target deconvolution has a reputation as a major bottleneck in phenotypic drug development, advances allowing for rapid identification of specific receptors for...


Discovery & Development of Inhaled Biopharmaceuticals

With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater in terms of helping the drug discovery community as a whole. The creation and subsequent development of inhaled biologics has become highly significant as it is now the route of choice for the delivery of numerous drugs. This is especially the case with...


An Update On Hepatitis B (HBV) Therapies

The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant burden it places on communities across the globe, hepatitis had been mainly ignored as a health and clinical development priority until recently. Hepatitis B infections are a leading cause of disability and death worldwide. In fact, hepatitis causes as many deaths annually as tuberculosis, AIDs or malaria....


Is The Cloud Enabling Bioinformatics To Become The Biology Solutions Domain?

For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that have been labelled as such have not been expansive – albeit they are biology centric. In this episode we look at the history and the challenges that exist in the biology field and examine how the cloud, ‘appification’,...


How The B6 Mouse Strain Is Revolutionising Drug Discovery

Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research. Understanding the B6 mouse, its origins, characteristics and potential is required to make full and appropriate use of this model in research and drug discovery. The B6 mouse is a versatile and powerful tool in preclinical research. These mice form the basis for many...


Technology Innovation Will Help Prepare Drug Discovery For The Smart Screening Era

Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds. We are on the cusp of having previously unimaginable amounts of information about each target and many more targets to prosecute. Thanks to more frequent co-operative hit discovery programmes, the need for increased screening capacity is pronounced. As we learn so much more about targets, drug discovery scientists must have access not only to more...


Raising The Bar On The Biologics Potential

In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. With budgets being tight and time scarce, outsourcing has become more common. Additionally, risk, perception and regulation have limited the adoption of biologics, biosimilars and biobetters, as small molecules and...


Collaborative Robots Are Redefining Lab Automation

The use of robots to automate high-volume repetitive tasks has been common practice going back to the early 1970s. Recent advances in robot technology are going to change the breadth of applications suitable for robots and alter how we think about robotic integration. For researchers in the drug discovery and development space, these advancements will open up many new possible ways of thinking through automation, delivering high productivity gains and ultimately reducing drug discovery...


Therapeutic Antibodies - New tools to enhance the antibody drug pipeline

Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to specifically, sensitively and reproducibly measure the concentration and bioavailability of these drugs in pharmacokinetic assays. We discuss the rise of therapeutic antibodies in drug discovery in favour of traditional small molecules and issues around the development of...


The Importance Of Heterocyclic Compounds In Anti-Cancer Drug Design

Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their structures. In this episode, we look at some of the most important heterocyclic compounds currently implicated in cancer therapy, both on the market and in development, discuss the properties that make them valuable as anti-cancer...


Immuno-Oncology's Biomarker Dilemma - How To Add Value In An Uncertain Development Landscape

Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated. Understanding the role biomarkers can play in this emerging treatment landscape has large implications, especially for companies seeking to launch new drugs and...


Drug Discovery In The Age Of Big Data – The Impact Of RNAi & CRISPR/Cas9 Technologies

This episode discusses how RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era. Most, if not all, consumers are feeling the weight of rising drug costs. But while much of the controversy surrounding rising drug prices has focused on a handful of pharmaceutical companies that have snapped up old drugs and then aggressively raised prices, the fact is that drug prices are far more likely to further increase due to the...


Phenotypic Screening - Advancing The Science From Discovery To Regulatory Science

Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems. Integration of phenotypic drug discovery approaches with target-based screening can improve success rates as assays can be leveraged for the discovery of novel mechanisms and for building knowledge of disease biology. The article was written by Dr Ellen L. Berg who is Chief Scientific Officer at DiscoverX If you'd like to view the original...


UX Design - Maximising The Value Of Scientific Software In Life Science R&D

Using scientific software can be frustrating and time-consuming, resulting in less productive research. This episode aims to demonstrate that User Experience (UX) Design – an evidence-based design process that centres on the behaviours and needs of users – offers specific efficiency benefits for life science R&D. Already well-established in other industries, such as retail and finance, UX design holds great unlocked potential for scientific software design. Because it offers a clear path...